Preparing to strike

With $100 million in hand Ascletis BioScience Co. Ltd. is poised to repeat what it has done in HCV by hunting for new liver therapies for the China market.

On Jan. 3, Ascletis closed an untranched $100 million series B round led by existing investor C-Bridge Capital. New investors QianHai Equity Investment, Focus Media Jiangnanchun Foundation and WTT Investment also participated, along with existing investors Goldman Sachs and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535)...